Sweet Syndrome Following SARS-CoV2 Vaccination

Abstract

Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.

Sweet Syndrome following SARS‐CoV‐2 CoronaVac vaccine

“… 2 , 3 To the best of our knowledge, only four cases of SS after COVID‐19 vaccines have been reported and no case of SS induced by CoronaVac vaccine has been reported. 4 Two of them, like in our case, had only cutaneous involvement and were related to the SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine. 4 The two other cases displayed extracutaneous manifestations such as polymyositis, arthritis, acute encephalitis and myoclonus and were associated with ChAdOx1 nCoV‐19 vaccine (Oxford‐AstraZeneca) and Moderna mRNA‐vaccine.…”

“… 4 The two other cases displayed extracutaneous manifestations such as polymyositis, arthritis, acute encephalitis and myoclonus and were associated with ChAdOx1 nCoV‐19 vaccine (Oxford‐AstraZeneca) and Moderna mRNA‐vaccine. 4 Our case is particular to have the shortest latency period between the vaccine and the skin eruption while in the other cases this period was between 24 and 96 h. This short latency time strongly supports the pathogenic role of the vaccine as a cause of SS in our case.…”

Cutaneous reactions to COVID-19 vaccines: A review

“…For the 8 vaccines that were studied, the most common local injection site reaction was pain (36, median duration of the onset of chilblains following COVID-19 vaccination was 3 days. Other less-common cutaneous reactions reported following COVID-19 vaccination included erythema multiforme (0.02%), [17][18][19][20][21][22][23][24] Sweet syndrome (0.012%), 18,[25][26][27][28] dermal hypersensitivity reactions (0.01%), 17 lichen planus (0.006%), 29,30 papulovesicular eruptions (0.006%), 17 pityriasis rosea-like eruptions (0.004%), 31,32 generalized annular lesions (0.002%), 33 facial pustular neutrophilic eruptions (0.004%), 34 and flares of underlying autoimmune skin conditions (0.002%). 35 All the cases resolved, without serious sequelae.…”

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult

“…They also rarely reported pernio/chilblains, cosmetic filler reactions, zoster, and pityriasis rosea-like reactions, but no PG [7]. Similarly, Sweet syndrome is a rare neutrophilic dermatosis affecting all layers of the skin with or without true vasculitis and most commonly idiopathic, but several drugs have been reported to induce it, and it was recently reported in a 52-year-old Caucasian man three days after receiving the first dose of the BNT162b2 vaccine [8]. Several theories regarding its pathogenesis have emerged, including hypersensitivity to bacterial or viral of 7 antigens that may trigger neutrophilic activation and subsequent infiltration [9].…”